You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,796,426

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,796,426

Title:	Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
Abstract:	The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and uses thereof.
Inventor(s):	Neri; Dario (Zurich, CH), Menssen; Hans Dietrich (Berlin, DE), Menrad; Andreas (Cambridgeshire, GB), Schliemann; Christoph (Zurich, CH)
Assignee:	Philogen S.p.A. (Sienna, IT)
Application Number:	12/270,174
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,796,426
Patent Claims:	1. A combination comprising at least (i) a fusion protein comprising two parts, wherein the first part is an antibody which specifically recognizes an extra domain B (ED.sub.b) of fibronectin, and the second part is an Interleukin-2 polypeptide which comprises the amino acid sequence set forth in SEQ ID NO: 4; and (ii) rituximab. 2. A combination according to claim 1, wherein the antibody and the Interleukin-2 of said fusion protein are linked by a fusion protein linker. 3. A combination according to claim 1, wherein the antibody of (i) recognizes the ED.sub.b domain of fibronectin and specifically binds thereto with sub-nanomolar or nanomolar affinity. 4. A combination according to claim 1, wherein the antibody comprises complementarity determining region (CDR) sequences comprising VH-CDR1-3 sequences and VL-CDR1-3 sequences of the L19 antibody. 5. A combination according to claim 4, wherein the VH-CDR1-3 sequences are set forth in SEQ ID NO:6, SEQ ID NO:8 and SEQ ID NO:7, respectively; and the VL-CDR1-3 sequences are set forth in SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11. 6. A combination according to claim 1, wherein the antibody comprises at least one Variable heavy (VH) chain according to SEQ ID NO: 1 or at least one Variable light (VL) chain according to SEQ ID NO: 2. 7. A combination according to claim 1, wherein the antibody comprises one VH (variable heavy) chain according to SEQ ID NO: 1 and one VL (variable light) chain according to SEQ ID NO: 2. 8. A combination according to claim 1, wherein the antibody comprises at least one Variable heavy (VH) chain according to SEQ ID NO: 1 and at least one Variable light (VL) chain according to SEQ ID NO: 2, wherein the variable heavy chain and the variable light chain are connected by an antibody linker. 9. A combination according to claim 8, wherein the antibody linker is a polypeptide comprising at least 90% sequence identity to the polypeptide sequence set forth in SEQ ID NO: 3. 10. A combination according to claim 1, wherein the antibody and the Interleukin-2 are connected by a fusion protein linker. 11. A combination according to claim 10, wherein the fusion protein linker has a length of 1 to 30 amino acids. 12. A combination according to claim 10, wherein the fusion protein linker comprises the sequence set forth in SEQ ID NO: 5. 13. A pharmaceutical composition which comprises a combination according to claim 1 and a carrier. 14. A method for the treatment of lymphoma in a subject in need thereof, comprising administering into said subject, the combination according to claim 1. 15. A method according to claim 14, wherein the lymphoma is a B-cell lymphoma. 16. A method according to claim 15, wherein the B-cell lymphoma is non-Hodgkin's lymphoma. 17. A method for the treatment of an autoimmune disease in a subject in need thereof, comprising administering into said subject, the combination according to claim 1. 18. A method according to claim 17, wherein the autoimmune disease is rheumatoid arthritis, Crohn's disease, colitis ulcerosa or autoimmune hemolytic anemia.

Details for Patent 8,796,426

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2028-01-17
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2028-01-17
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2028-01-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.